Skip to content

An Interactive Smartphone Application to Motivate Smokers to Quit

An Interactive Smartphone Application to Motivate Smokers to Quit

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05799625
Acronym
StepOne
Enrollment
382
Registered
2023-04-05
Start date
2024-03-12
Completion date
2026-12-01
Last updated
2026-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking Behaviors, Smoking Cessation

Brief summary

Prospective, randomized, single-blinded, blinded-endpoint trial to determine the impact of a smartphone application-based program to motivate smokers to increase readiness to quit, make quit attempts, and quit smoking.

Detailed description

Prospective, randomized, single-blinded, blinded-endpoint trial to determine the impact of a smartphone application-based program to motivate smokers to increase readiness to quit, make quit attempts, and quit smoking. The intervention has been designed based by a team of scientist, taking principles of change behaviour into consideration. The application incorporates daily reminders, gamification, and models of habit formation to engage users. It will support participants to reflect on their smoking in a holistic manner through questions and activities.

Interventions

BEHAVIORALStepOne Smartphone Application

This smartphone application provides a 14-day program that delivers the core components of smoking cessation (i.e., counseling, education) and takes advantage of pandemic-accelerated acceptance of virtual care, videoconferencing, remote monitoring, and social networking. The program seeks to move participants from the pre-action stage (not interested in quitting) to the action stage (intention to quit) and incorporates daily reminders, gamification, and models of habit formation to engage users.

Sponsors

Ottawa Heart Institute Research Corporation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age or older. * Living in Ontario, Canada. * Current smoker who indicates they are not interested in quitting within the next 30-days. * Have access to and regularly use a smartphone with internet access. * Read, write, speaks English or French. * Available and willing to participate in follow-up assessments over the next 6 months. * Able to provide consent.

Exclusion criteria

* Planning on quitting smoking within the next 30-days. * Cognitively impaired or experiencing acute psychiatric illness that would alter their ability to participate. * Institutionalized at a retirement home, nursing home or long-term care facility. * Has morbid illness which will prevent completion of 6-month follow-up (e.g., receiving palliative care). * Participating in another smoking cessation program

Design outcomes

Primary

MeasureTime frameDescription
Self-reported readiness to quitDay 14Collected via survey
Having made a quit attemptDay 14Collected via survey
Rate of smoking cessationDay 45 for participants who report smoking cessationBiochemically verified using an expired carbon monoxide (CO) test

Secondary

MeasureTime frameDescription
Number of participants that made a quit attemptDay 14, 45, 195Collected via survey
Change in smokingDay 14, 45, 195Collected via survey
Point prevalence abstinenceDay 14, 45, 195Collected via survey
Use of behavioural supports (e.g. counselling, quit lines)Day 14, 45, 195Collected via survey
Use of cessation medication and/or e-cigarettesDay 14, 45, 195Collected via survey
Satisfaction and perceived program barriers and facilitators will be assessed for patients in the intervention groupDay 14, 45, 195Collected via survey

Countries

Canada

Contacts

PRINCIPAL_INVESTIGATORHassan Mir, MD

The University of Ottawa Heart Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026